GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Yeni İş İlişkisi 4 Mayıs 2026

-Unofficial Translation-

A Promotion, Sales, Distribution and Marketing Authorization Transfer Agreement has been signed between the two companies, effective for a period of 5 (five) years starting on May 1, 2026, for the purpose of Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GEN) exclusively conducting business operations and transactions in Türkiye, related to the sales, marketing, promotion and distribution of the products listed below, for which Pfizer PFE İlaçları Anonim Şirketi is the marketing authorization holder.

ELELYSO® 200 U Lyophilized Powder for IV Infusion Solution: It is used in the treatment of Gaucher Disease, a rare, genetic, and hereditary metabolic disorder characterized by the accumulation of certain fatty substances (lipids) in organs such as the spleen, liver, and bone marrow due to their inability to be broken down.

BESPONSA 1 mg Powder for Concentrate for the Preparation of Infusion Solution: It is used in the treatment of patients diagnosed with Precursor B-cell Acute Lymphoblastic Leukemia (ALL)—an aggressive type of blood cancer caused by the uncontrolled and rapid proliferation of lymphoblasts (the precursors of white blood cells known as lymphocytes) in the bone marrow—who are Philadelphia chromosome-negative and demonstrate CD22 positivity as confirmed by histopathological or flow cytometric analysis.

In case of any discrepancy between the Turkish and English texts, the Turkish text shall prevail.